Clinical approaches to the development of a neuroprotective therapy for PD

Experimental Neurology

Volumn 298, Issue , 2017, Pages 246-251

  Olanow, C W ^a,b   Kieburtz, K ^a,c   Katz, R ^a,d  

^a Clintrex LLC   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Neuroprotection; Parkinson disease

Indexed keywords

ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; BIOLOGICAL MARKER; DOPAMINE; LEVODOPA; OMIGAPIL; PLACEBO; RASAGILINE; SELEGILINE; UBIDECARENONE; NEUROPROTECTIVE AGENT;

CELL TRANSPLANTATION; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG APPROVAL; HEALTH CARE POLICY; HUMAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; UNIFIED PARKINSON DISEASE RATING SCALE; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; PHYSIOLOGY;

ANIMALS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 85021415460     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2017.06.018     Document Type: Review

References (30)

1. Ahlskog, J.E., Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 60 (2003), 381–389.
2. Alterman, R.L., Tagliati, M., Olanow, W., Observer bias in biological/surgical trials of novel Parkinson's disease therapies. Mov. Disord., 24, 2009, 254.
3. Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C.W., Tanner, C., Marek, K., Parkinson Study Group, Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351 (2004), 2498–2508.
4. Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J.Q., Eidelberg, D., Fahn, S., Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344 (Mar 8 2001), 710–719.
5. Freeman, T.B., Olanow, C.W., Hauser, R.A., et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann. Neurol. 38 (1995), 379–388.
6. Hauser, R.A., Holford, N.H., Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov. Disord. 17 (2002), 961–968.
7. Kieburtz, K., Tilley, B.C., Elm, J.J., et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD). JAMA 313 (2015), 584–593.
8. Kordower, J.H., Olanow, C.W., Dodiya, H.B., Chu, Y., Beach, T.G., Adler, C.H., Halliday, G.M., Bartus, R.T., Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136 (2013), 2419–2431.
9. Kozauer, N., Katz, R., Regulation of drugs for early Alzheimer's disease. N. Engl. J. Med., 369, 2013, 288.
10. Larsen, J.P., Boas, J., Erdal, J.E., Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur. J. Neurol. 6 (1999), 539–547.
11. Leber, P., Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis. Assoc. Disord. 11:Suppl. 5 (1997), S10–S21 (discussion S37-9).
12. Marks, W.J. Jr., Ostrem, J.L., Verhagen, et al. Gene transfer of a trophic factor for PD: initial clinical trial with AAV2-neurturin (CERE-120). Lancet Neurol. 7 (2008), 400–408.
13. Marks, W., Bartus, R., Siffert, J., Starr, P., Ostrem, J., Larson, P., Stacy, M., Boulis, N., Vitek, G., Verhagen, L., Watts, R., Jankovic, J., Tagliati, M., Stern, M., Nutt, J., Davis, C., Lozano, C., Kieburtz, K., Kordower, J., Olanow, C.W., Double-blind, sham-surgery controlled trial of gene delivery of AAV2-neurturin for Parkinson's disease. Lancet Neurol. 9 (2010), 1164–1172.
14. Olanow, C.W., Kieburtz, K., Defining disease-modifying therapies for PD—a road map for moving forward. Mov. Disord. 25 (2010), 1774–1779.
15. Olanow, C.W., Hauser, R.A., Gauger, L., et al. The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease. Ann. Neurol. 38 (1995), 771–777.
16. Olanow, C.W., Goetz, C.G., Kordower, J.H., Stoessl, J., Sossi, V., Brin, M.F., Shannon, K.M., Perl, D.P., Godbold, J., Freeman, T.B., A double blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54 (2003), 403–414.
17. Olanow, C.W., Schapira, A.H.V., Lewitt, P.A., et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 5 (2006), 1013–1020.
18. Olanow, C.W., Stern, M.B., Sethi, K., Scientific and clinical basis for the treatment of PD – 2009. Neurology 72:Suppl. 4 (2009), S1–136.
19. Olanow, C.W., Rascol, O., Hauser, R., Feigin, P., Jankovic, J., Lang, A.E., Langston, W., Melamed, E., Poewe, W., Stocchi, F., Tolosa, E., A double-blind delayed-start study of rasagiline in early Parkinson's disease. N. Engl. J. Med. 361 (2009), 1268–1278.
20. Olanow, C.W., Bartus, R.T., Baumann, T., et al. Gene delivery of AAV2-neurturin to putamen and substantia nigra in Parkinson's disease: a double-blind, randomized, controlled trial. Ann. Neurol. 78 (2015), 248–257.
21. Pålhagen, S., Heinonen, E., Hägglund, J., Kaugesaar, T., Mäki-Ikola, O., Palm, R., Swedish Parkinson Study Group, Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66 (2006), 1200–1206.
22. Parkinson Progression Marker Initiative (PPMI), Prog. Neurobiol. 95 (2011), 629–635.
23. Parkinson Study Group, Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284 (2000), 1931–1938.
24. Parkinson Study Group, A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 71 (2014), 543–552.
25. Parkinson's Study Group, Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328 (1993), 176–183.
26. Postuma, R., Berg, D., Adler, C.H., Bloem, B.R., Chan, P., Deuschl, G., Gasser, T., Goetz, C.G., Halliday, G., Joseph, L., Lang, A.E., Liepelt-Scarfone, I., Litvan, I., Marek, K., Oertel, W., Olanow, C.W., Poewe, W., Stern, M., The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol. 15 (2016), 546–548.
27. Rascol, O., Brooks, D.J., Korczyn, A.D., De Deyn, P.P., Clarke, C.E., Lang, A.E., A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med. 342 (2000), 1484–1491.
28. Rascol, O., Hauser, R.A., Stocchi, F., Fitzer-Attas, C., Sidi, Y., Abler, V., Olanow CW for the AFU investigators. Long term effects of rasagiline, and the natural history of treated Parkinson's disease: results from the ADAGIO Follow-up Study. Mov. Disord. 31 (2016), 1489–1496.
29. Shults, C.W., Oakes, D., Kieburtz, K., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59 (2002), 1541–1550.
30. Tilley, B.C., Palesch, Y.Y., Kieburtz, K., et al. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 66 (2006), 628–633.